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RET is a receptor tyrosine kinase that is normally involved in signaling processes during embryonic 
development and contributes to normal function in several types of adult cells. Aberrant activity of 
the RET gene, which results from activating mutations, can contribute to the growth of several types 
of human cancers, demonstrating that RET can be an oncogene. However, Dr. William Grady's lab 
in the Clinical Research Division has recently suggested that RET may also have a role as a tumor 
suppressor in colorectal cancer. The authors show that the expression ofRET is decreased in colon 
cancer samples relative to normal colon epithelium as a result of aberrant and excessive DNA 
methylation. In addition, they show that some tumors have inactivating mutations in the gene, which 
inhibit RET's ability to promote apoptosis. 
RET is a well-characterized oncogene. Genetic rearrangements of RET with a variety of activating 
genes results in inappropriate expression patterns and the creation of fusion proteins that are 
constitutively active. Furthermore, germline mutations resulting in a constitutively active RET have 
been found to drive certain types of inherited endocrine cancers. Thus, lead authors Drs. Yanxin Luo 
and Karen Tsuchiya were surprised to identify RET as a gene that is hypermethylated, and whose 
expression is downregulated, in colorectal cancer. 
Using a genome-wide screen to identify genes that are abnormally methylated in colorectal cancer, 
Luo et al. identified DNA hypermethylation of RET in colon cancer cell lines. The authors also 
verified the frequency of its methylation in advanced benign adenomas (27%) and pathogenic 
adenocarcinomas (63%). RET expression was significantly decreased in cell lines and tumors that 
had methylated RET compared to those that did not, and this expression could be restored by 
treatment of the cells with a DNA-demethylating agent. 
The authors suggest that RET may function as a tumor suppressor in colorectal cancer by inducing 
apoptosis when this receptor tyrosine kinase is not bound to one of its four ligands. One of these 
ligands, GDNF, is expressed in normal colon epithelia, but not in colon cancer. 
Ectopic RET expression was sufficient to induce cell death by apoptosis, but this could be blocked 
by treating the cancer cell lines with the RET ligand GDNF. Introduction of RET variants that  
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contained inactivating mutations that are often observed in human colorectal cancers was unable to 
induce apoptosis. Finally, knockdown of endogenous RET in cell lines promoted colony formation on 
soft agar, a method for assessing tumorigenecity in vitro. 
Thus, the role of RET in tumor development appears to be complex and highly dependent on the 
cellular context in which it is expressed. In colon epithelia, RET appears to serve as a tumor 
suppressor by promoting apoptosis. However, normal colon epithelia expresses the RET ligand 
GDNF, preventing aberrant apoptosis. To overcome the apoptotic effects of RET in the absence of 
GDNF, this study suggests that colon cancer cells block the expression or function of RET through 
DNA hypermethylation or inactivating mutations. 
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Expression of RET in normal colon epithelium (brown staining areas) 
and colon cancer. 
 
